Stim Culture

The Sprawl consumes 2.3 billion stim doses per day. Helix Biotech's Q3 2184 earnings report lists this figure under "Wellness Engagement." Wholesome's annual sustainability brief rounds it to "broad-spectrum nutritional supplementation across all demographics." Neither company uses the word "dependency" in public-facing materials.

Helix's internal pharmacological database — accessed through a 2183 data breach that produced no arrests and one retracted press inquiry — contains 4,100 pages of dependency profile research on its six best-selling cognitive accelerators. The published version is eleven pages. The eleven pages recommend "continued use under medical supervision."

Stim culture is not a subculture. It is the culture.

Wholesome sells ClearMind capsules at every G Nook checkout counter, packaged in soft greens and marketed as "cognitive wellness." The active compound is a caffeine analogue bonded to a nootropic that Wholesome's own R&D team internally designated NX-7 before marketing renamed it "NeuroNourish." NX-7's dependency onset averages 18 days at recommended dosage. Recommended dosage is printed on the label. The dosage required to maintain the cognitive baseline established during those 18 days is not.

Helix occupies the premium tier. Its prescription-grade accelerators — Lucidex, SynaptiCore, the injectable Cognivex line — are dispensed through licensed augmentation clinics for "performance maintenance." The licensing requirement creates a bottleneck that Helix controls at both ends: Helix certifies the clinics, Helix manufactures the product, Helix publishes the dosage guidelines, and Helix operates the rehabilitation centers where patients go when the dosage guidelines prove insufficient. Revenue per patient across the full lifecycle averages ¢34,700 annually. Helix's investor briefings refer to this as "continuity of care."

The street trade fills the gap between what Wholesome sells cheaply and what Helix sells expensively. Unlicensed chemists in the Dregs synthesize analogues from industrial precursors and sell them in foil packets. The product names are better than the products: Brainfire, Neon Thought, CrashProof. CrashProof is the best-selling street stim in Sector 9. Its dependency onset is six days. Nobody has successfully sued the manufacturer over the name, because the manufacturer is fourteen people operating from nine locations, none of which exist on consecutive days.

Dependency Economics

The arithmetic is the trap, and the arithmetic is simple.

A Sector 7 logistics coordinator earning ¢2,100 per week takes ClearMind to handle the cognitive load of managing 340 drone routes simultaneously — a task performed by four people before Nexus Dynamics' 2179 workforce optimization. Her enhanced output becomes the performance baseline her supervisor measures against. After 18 days, removing the ClearMind doesn't return her to her previous cognitive capacity. It drops her 15–20% below it — a withdrawal deficit that Wholesome's published literature describes as "temporary adjustment" and Helix's unpublished research identifies as "semi-permanent receptor downregulation." Her choice is ¢22 per week on ClearMind or a performance review she cannot pass.

She is not addicted. She is employed.

The Rothwell Foundation's consumer wellness division conducted a survey in 2182 asking Sprawl residents whether they considered their stim use "voluntary." Eighty-three percent said yes. The same survey found that 71% of respondents could not perform their current job duties without stims. The survey did not ask respondents to reconcile these numbers. The published findings were titled "Consumer Choice in the Wellness Marketplace."

Corporate-tier stim culture is quieter and more expensive. Executive-grade Cognivex injections are administered in private clinic suites with leather chairs and ambient music. The dependency profile is identical to the street-grade analogues — receptor downregulation, baseline erosion, withdrawal deficit — but the packaging includes a Helix-certified "cognitive continuity plan" costing ¢4,200 per month. The plan ensures the executive never experiences the withdrawal the logistics coordinator manages every weekend she can't afford her refill. The pharmacology is the same. The price difference purchases uninterrupted dependency.

Wholesome sells performance to workers who need it to keep their jobs. Nexus Dynamics designed the jobs that made the performance necessary. Helix sells the recovery program when the performance breaks the worker. Good Fortune finances the gap between all three. None of these companies are in the same industry.

Stim Crash

Stim Crash is the withdrawal state, and on the Neon Rail it's as common as blisters.

The clinical presentation: fatigue that sits behind the eyes like wet concrete. Cognitive fog — not the gentle kind, the kind where you can't remember the word for the thing you're holding. Fine motor tremor in the hands. A depression that feels chemical because it is, arriving on schedule approximately 14 hours after the last dose, peaking at 36 hours, and resolving — if "resolving" is the right word — sometime around day five. The stabilized state sits 15–20% below pre-stim baseline. Helix's literature calls this "the new normal." It is not a selling point. It is a sales mechanism.

Rest helps. Time helps. The Dregs clinics that treat Crash charge what they can, which is less than the stims cost, which is the only reason anyone goes.

Helix operates four branded recovery centers in the Heights. Their Crash protocol takes nine days, costs ¢8,400, and concludes with a "maintenance prescription" for a lower-dose Helix product designed to ease the transition. Sixty-two percent of patients who complete the protocol are back on full-dose stims within four months. Helix's outcomes reporting counts the protocol completion as a success. The four-month relapse falls under a different department's metrics.

The Underground

Below the Sprawl's manufactured floors, stim culture grows literally.

Wild stim plants — mutant vegetation that thrives in tunnel environments where contaminated runoff and trace industrial chemistry produce pharmacologically active root systems — are scavenged by Neon Rail travelers as supplemental food and medicine. The plants are edible in the way that most things are edible if you're hungry enough: caloric content is marginal, the taste has been described as "dirt that fights back," and the mild stimulant effect is approximately equivalent to two ClearMind capsules or one strong opinion about being alive. Dependency onset for the wild strains is slower than the manufactured products — months rather than days — which travelers interpret as evidence that the plants are safer. The dependency is the same. The timeline is more polite about it.

Tunnel growers have established informal cultivation sites along the Rail's deeper stretches, tending patches of wild stim with the attentive care of people who understand that the thing keeping them functional is also the thing they can't stop needing. The growers trade among themselves in a barter economy that Wholesome's supply chain analytics have never mapped, because mapping it would require acknowledging that a competing product exists, and the competing product is a weed.

Open Questions

Related Systems

• Wholesome — Manufactures consumer-grade stims as "wellness supplements." ClearMind is the Sprawl's best-selling cognitive product by unit volume. The packaging says "nourish your potential."
• Helix Biotech — Produces medical-grade cognitive stims prescribed for "performance maintenance." Controls the full patient lifecycle from prescription through dependency through rehabilitation through re-prescription.
• The Neon Rail — Where Stim Crash is a travel condition rather than a medical event. Wild stim plants along the route are both resource and risk for long-haul travelers.
• Nexus Dynamics — Workforce optimization algorithms created the cognitive demands that stims were purchased to meet. Nexus does not sell stims. Nexus sells the conditions under which stims become necessary.
• Good Fortune — Offers StimSure credit lines: micro-loans structured specifically for recurring wellness purchases. Interest compounds monthly. The average StimSure borrower's repayment timeline exceeds their projected dependency duration by a factor of three.
• The Rothwell Foundation — Publishes the annual Wellness Marketplace survey that frames dependency as consumer choice. The survey methodology has been peer-reviewed and found technically sound. The questions it declines to ask have not been reviewed by anyone.